BLAINJECTIONINJECTABLE
Approved
Aug 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
SKYTROFA (lonapegsomatropin-tcgd) by Ascend Therapeutics. Approved for growth hormone deficiency, adult growth hormone deficiency. First approved in 2021.
Drug data last refreshed 20h ago
Mechanism of Action
Pharmacologic Class:
Recombinant Human Growth Hormone
Indications (2)
Clinical Trials (1)
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
Started Mar 2023
900 enrolled
Growth Hormone Deficiency
Worked on SKYTROFA at Ascend Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.